TY - JOUR
T1 - Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: In Vitro and In Vivo studies
AU - Mutalik, Srinivas
AU - Manoj, Krishnan
AU - Reddy, Meka Sreenivasa
AU - Kushtagi, Pralhad
AU - Usha, Achutha Nayak
AU - Anju, Parambil
AU - Ranjith, Averineni Kumar
AU - Udupa, Nayanabhirama
N1 - Cited By :20
Export Date: 10 November 2017
Correspondence Address: Mutalik, S.; Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka 576104, India; email: ssmutalik@yahoo.com
Chemicals/CAS: aceclofenac, 89796-99-6; cellacefate, 9004-38-0; chitosan, 9012-76-4; dodecyl sulfate sodium, 151-21-3; hydrochloric acid, 7647-01-0; hydroxypropylmethylcellulose phthalate, 9050-31-1; magnesium stearate, 557-04-0; microcrystalline cellulose, 39394-43-9, 51395-75-6; povidone, 9003-39-8; talc, 14807-96-6; cellulose, 61991-22-8, 68073-05-2, 9004-34-6; diclofenac, 15307-79-6, 15307-86-5; methylcellulose, 79484-92-7, 9004-67-5; aceclofenac, 89796-99-6; Anti-Inflammatory Agents, Non-Steroidal; cellulose acetate phthalate, 9004-38-0; Cellulose, 9004-34-6; Chitosan, 9012-76-4; Delayed-Action Preparations; Diclofenac, 15307-86-5; Drug Carriers; hydroxypropyl methylcellulose phthalate, 9050-31-1; Methylcellulose, 9004-67-5; Tablets, Enteric-Coated
Tradenames: hifenac, Intas, India
Manufacturers: Intas, India; Lupin Laboratories, India
References: Parfitt, K., Analgesics, anti-inflammatory and antipyretics (1999) Martindale: The Complete Drug Reference, pp. 1-12. , In J. E. F. Reynolds (ed.) 32nd ed, Massachusetts; Kay, A.E., Alldred, A., Rheumatoid arthritis and osteoarthritis (2003) Clinical Pharmacy and Therapeutics, pp. 791-807. , In R. Walker, and C. Edwards (eds.) 3rd ed., Churchill Livingstone, London, UK; Moffet, A.C., Osselton, M.D., Widdop, B., (2006) Clarke' S Analysis of Drugs and Poisons, , 3rd ed., Pharmaceutical Press, London, UK; Rao, M.Y., Veni, J.K., Jayasagar, G., Formulation and evaluation of diclofenac sodium using hydrophilic matrices (2001) Drug. Dev. Ind. Pharm., 27, pp. 759-766; Maggi, L., Machiste, E.O., Torre, M.L., Conte, U., Formulation of biphasic release tablets containing slightly soluble drugs (1999) Eur. J. Pharm. Biopharm., 48, pp. 37-42; Chien, Y.W., Regulatory considerations in controlled release medication (1982) Novel Drug Delivery Systems, pp. 577-578. , In Y. W. Chien (ed.) Marcel Dekker, New York, NY; Mutalik, S., Naha, A., Usha, A.N., Preparation, in vitro, Preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac (2007) Arch. Pharm. Res., 30, pp. 222-234; George, M., Abraham, E.T., Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan - A review (2006) J. Controlled. Rel., 114, pp. 1-14; Fukuda, M., Nicholas, A.P., McGinity, J.W., Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum (2006) Int. J. Pharm., 310, pp. 90-100; Wang, K., Zhimin, H., Alginate-konjac glucomannan-chitosan beads as controlled release matrix (2001) Int. J. Pharm., 244, pp. 117-126; Barreiro-Iglesias, R., Coronilla, R., Concheiro, A., Alvarez-Lorenzo, C., Preparation of chitosan beads by simultaneous cross-linking/ insolubilisation in basic pH. Rheological optimisation and drug loading/ release behaviour (2005) Eur. J. Pharm. Sci., 24, pp. 77-84; Akbua, J., Use of chitosonium malate as a matrix in sustained-release tablets (1993) Int. J. Pharm., 89, pp. 19-24; Knapczyk, J., Antimycotic buccal and vaginal tablets with chitosan (1992) Int. J. Pharm., 88, pp. 9-14; Reddy, K.R., Mutalik, S., Reddy, S., Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluation (2003) AAPS PharmSciTech., 4, pp. E61; Agrawal, A.M., Neau, S.H., Bonate, P.L., Wet granulation fine particle ethylcellulose tablets: Effect of production variables and mathematical modeling of drug release (2003) AAPS PharmSci., 2. , Article 13; Chen, R., Takahashi, H., Okamoto, H., Danjo, K., Particle design of three-component system for sustained release using a 4-fluid nozzle spray-drying technique (2006) Chem. Pharm. Bull., 11, pp. 1486-1490; Silva, C.M., Ribeiro, A.J., Ferreira, D., Veiga, F., Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation (2006) Eur. J. Pharm. Sci., 2, pp. 148-159; Aulton, M.E., Wells, T.I., (1988) Pharmaceutics-The Science of Dosage Form Design, , Churchill Livingstone, London, UK; (1996) Indian Pharmacopoeia. Ministry of Health and Family Welfare, 2. , Government of India Delhi, India: Controller of Publication; Joshi, B.V., Patil, V.B., Pokharkar, V.B., Compatibility studies between carbamazepine and tablet excipients using thermal and non-thermal methods (2002) Drug Dev. Ind. Pharm., 6, pp. 687-694; Kibbe, H.A., (2000) Hand Book of Pharmaceutical Excipients, , 3rd ed. American pharmaceutical association, Pharmaceutical press, London; Seitz, J.A., Mehta, S.P., Yeager, J.L., Tablet coating (1987) The Theory and Practice of Industrial Pharmacy, pp. 346-373. , In L. Lachman, H. A. Liberman, and J. L. Kanig (eds.) 3rd ed., Varghese Publishing House, Delhi, India; Banakar, U.V., Dissolution of modified release dosage forms (1992) Pharmaceutical Dissolution Testing, pp. 299-312. , In J. Swarbrick (ed.) Marcel Dekker, New York, NY; Palmieri, G.F., Michelini, S., Martino, P.D., Martelli, S., Polymers with pH-dependent solubility: Possibility of use in the formulation of gastro resistant and controlled-release matrix tablets. Drug (2000) Dev Ind Pharm., 26, pp. 837-845; Yomota, C., Miyazaki, T., Okada, S., Sustained-release effect of the direct compressed tablet based on chitosan and Na alginate (1994) Yakugaku Zasshi., 114, pp. 257-263; Grundy, J.S., Anderson, K.E., Rogers, J.A., Foster, R.T., Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test (1997) J. Control Release., 48, pp. 9-17; Negrin, C.M., Delgado, A., Llabres, M., Evora, C., In vivo-in vitro study of biodegradable methadone delivery systems (2001) Biomaterials, 22, pp. 563-570; Yang, X., Zhang, G., Li, W., Peng, B., Liu, Z., Pan, W., Design and evaluation of Jingzhiguanxin monolithic osmotic pump tablet (2006) Chem. Pharm. Bull., 4, pp. 465-469
PY - 2008/6
Y1 - 2008/6
N2 - The purpose of this study was to develop a once daily sustained release tablet of aceclofenac using chitosan and an enteric coating polymer (hydroxypropyl methylcellulose phthalate or cellulose acetate phthalate). Overall sustained release for 24 h was achieved by preparing a double-layer tablet in which the immediate release layer was formulated for a prompt release of the drug and the sustained release layer was designed to achieve a prolonged release of drug. The preformulation studies like IR spectroscopic and differential scanning calorimetry showed the absence of drug-excipient interactions. The tablets were found within the permissible limits for various physicochemical parameters. Scanning electron microscopy was used to visualize the surface morphology of the tablets and to confirm drug release mechanisms. Good equivalence in the drug release profile was observed when drug release pattern of the tablet containing chitosan and hydroxypropyl methylcellulose phthalate (M-7) was compared with that of marketed tablet. The optimized tablets were stable at accelerated storage conditions for 6 months with respect to drug content and physical appearance. The results of pharmacokinetic studies in human volunteers showed that the optimized tablet (M-7) exhibited no difference in the in vivo drug release in comparison with marketed tablet. No significant difference between the values of pharmacokinetic parameters of M-7 and marketed tablets was observed (p > 0.05; 95% confidence intervals). However the clinical studies in large scale and, long term and extensive stability studies at different conditions are required to confirm these results. © American Association of Pharmaceutical Scientists 2008.
AB - The purpose of this study was to develop a once daily sustained release tablet of aceclofenac using chitosan and an enteric coating polymer (hydroxypropyl methylcellulose phthalate or cellulose acetate phthalate). Overall sustained release for 24 h was achieved by preparing a double-layer tablet in which the immediate release layer was formulated for a prompt release of the drug and the sustained release layer was designed to achieve a prolonged release of drug. The preformulation studies like IR spectroscopic and differential scanning calorimetry showed the absence of drug-excipient interactions. The tablets were found within the permissible limits for various physicochemical parameters. Scanning electron microscopy was used to visualize the surface morphology of the tablets and to confirm drug release mechanisms. Good equivalence in the drug release profile was observed when drug release pattern of the tablet containing chitosan and hydroxypropyl methylcellulose phthalate (M-7) was compared with that of marketed tablet. The optimized tablets were stable at accelerated storage conditions for 6 months with respect to drug content and physical appearance. The results of pharmacokinetic studies in human volunteers showed that the optimized tablet (M-7) exhibited no difference in the in vivo drug release in comparison with marketed tablet. No significant difference between the values of pharmacokinetic parameters of M-7 and marketed tablets was observed (p > 0.05; 95% confidence intervals). However the clinical studies in large scale and, long term and extensive stability studies at different conditions are required to confirm these results. © American Association of Pharmaceutical Scientists 2008.
UR - http://www.scopus.com/inward/record.url?scp=51449111668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51449111668&partnerID=8YFLogxK
U2 - 10.1208/s12249-008-9075-3
DO - 10.1208/s12249-008-9075-3
M3 - Article
C2 - 18500561
AN - SCOPUS:51449111668
SN - 1530-9932
VL - 9
SP - 651
EP - 659
JO - AAPS PharmSciTech
JF - AAPS PharmSciTech
IS - 2
ER -